GYRE THERAPEUTICS, INC. (GYRE)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch GYRE
See up to 3 months of GYRE. The 7-day demo opens the 1M and 3M ranges and puts GYRE on your watchlist.
Start 7-day demoLatest GYRE insider trades
About GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. files with the SEC under CIK 0001124105 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
GYRE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 80,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
GYRE insider transactions (Form 4)
7845 Form 4 filings on record, the earliest from Dec 19, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Claire Weston - Director | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Maxwell Kirkby - Director | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Gordon Carmichael | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| David M. Epstein | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Dan Weng | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Renate Parry | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Ping Zhang | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Rodney L. Nussbaum | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 3,000 | $0.75 | $2K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 3,000 | $6.15 | $18K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 5,000 | $0.75 | $4K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 3,000 | $0.75 | $2K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 3,000 | $6.35 | $19K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 5,000 | $6.24 footnote F1 | $31K | |
| ||||||
| Weiguo Ye - Officer | Option exercise | Common Stock | 2,800 | $0.75 | $2K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 2,800 | $6.17 footnote F1 | $17K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 2,800 | $0.00 | - | |
| ||||||
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 14,500 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 6,418 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 14,500 | $0.75 | $11K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 6,418 | $0.75 | $5K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 14,500 | $6.14 footnote F1 | $89K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 6,418 | $6.21 footnote F2 | $40K | |
| ||||||
| Joshua Benjamin Bergmann - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
 Ying Luo - Officer | Grant or award | Stock Option (Right to Buy) | 120,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 19,575 | $0.75 | $15K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 15,401 | $0.75 | $12K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 19,575 | $6.13 footnote F1 | $120K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 15,401 | $6.40 footnote F2 | $99K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 19,575 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 15,401 | $0.00 | - | |
| ||||||
| Weiguo Ye - Officer | Option exercise | Common Stock | 3,500 | $0.75 | $3K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 4,000 | $0.75 | $3K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 4,000 | $6.10 | $24K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 3,500 | $6.08 footnote F1 | $21K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | - | |
| ||||||
| Weiguo Ye - Officer | Option exercise | Common Stock | 9,400 | $0.75 | $7K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 12,820 | $0.75 | $10K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 9,400 | $6.15 footnote F1 | $58K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 12,820 | $6.15 footnote F2 | $79K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 9,400 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 12,820 | $0.00 | - | |
| ||||||
| Ping Zhang | Derivative | Stock Option (Right to Buy) | 250,000 | $0.00 footnote F1 | - | |
| ||||||
| Weiguo Ye - Officer | Option exercise | Common Stock | 200 | $0.75 | $150 | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 9,120 | $0.75 | $7K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 200 | $6.62 footnote F1 | $1K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 9,120 | $6.37 footnote F2 | $58K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 200 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 9,120 | $0.00 | - | |
| ||||||
| Weiguo Ye - Officer | Option exercise | Common Stock | 15,580 | $0.75 | $12K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 13,100 | $0.75 | $10K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 15,580 | $6.91 footnote F1 | $108K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 13,100 | $6.65 footnote F2 | $87K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 15,580 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 13,100 | $0.00 | - | |
| ||||||
| Ying Luo - Officer | Open-market sale | Common Stock | 179 | $8.01 | $1K | |
| Ying Luo - Officer | Open-market sale | Common Stock | 10,136 | $8.04 footnote F2 | $81K | |
| ||||||
| GNI Group Ltd. | Other | Series B Preferred Stock | 458,120 footnote F2,F3 | - footnote F1 | - | |
| GNI Group Ltd. | Other | Series B Preferred Stock | 2,143,706 footnote F2,F3 | - footnote F1 | - | |
| ||||||
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 95,060 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 95,060 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 47,530 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 11,882 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 33,271 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 33,271 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 92,683 | $0.00 | - | |
| Ping Zhang | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Ruoyu Chen - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Dan Weng | Grant or award | Stock Option (Right to Buy) | 52,000 | $0.00 | - | |
| Ping Zhang | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Thomas Wilson Eastling | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
| David M. Epstein | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
| Rodney L. Nussbaum | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
| Renate Parry | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
Item 7.01, 9.01
Item 7.01, 9.01
Item 2.02, 9.01
Item 5.02, 7.01, 9.01
Recent GYRE Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
GYRE insider trading FAQ
What is the latest insider trade for GYRE?
GYRE THERAPEUTICS, INC. (GYRE) had 2 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for GYRE runs to 45 Form 4 filings, the earliest from 2024-12-19. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GYRE stock?
No insider purchases of GYRE were filed in the last 90 days.
How many insiders are selling GYRE stock?
No insider sales of GYRE were filed in the last 90 days. 42 sales are on record for this company.
Where can I see GYRE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GYRE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Claire Weston view on EDGAR
- - Maxwell Kirkby view on EDGAR
- - Gordon Carmichael view on EDGAR
- - David M. Epstein view on EDGAR
- - Dan Weng view on EDGAR
- - Renate Parry view on EDGAR
- - Ping Zhang view on EDGAR
- - Rodney L. Nussbaum view on EDGAR
- - Weiguo Ye view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where GYRE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GYRE with a 7-day demo
- GYRE on your watchlist
- Every GYRE Form 4 filing on record
- Up to 3 months of GYRE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
